BR112022022737A2 - Tratamento de esteatose hepática não alcoólica (ehna) - Google Patents
Tratamento de esteatose hepática não alcoólica (ehna)Info
- Publication number
- BR112022022737A2 BR112022022737A2 BR112022022737A BR112022022737A BR112022022737A2 BR 112022022737 A2 BR112022022737 A2 BR 112022022737A2 BR 112022022737 A BR112022022737 A BR 112022022737A BR 112022022737 A BR112022022737 A BR 112022022737A BR 112022022737 A2 BR112022022737 A2 BR 112022022737A2
- Authority
- BR
- Brazil
- Prior art keywords
- nash
- treatment
- hepatic steatosis
- alcoholic hepatic
- alcoholic
- Prior art date
Links
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 title abstract 3
- 206010019708 Hepatic steatosis Diseases 0.000 title abstract 2
- PIUZYOCNZPYXOA-ZHHJOTBYSA-N [(3s,8s,9s,10r,13r,14s,17r)-17-[(2r)-6-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCCC(C)(C)O)C)[C@@]1(C)CC2 PIUZYOCNZPYXOA-ZHHJOTBYSA-N 0.000 abstract 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063029361P | 2020-05-22 | 2020-05-22 | |
| US202063030207P | 2020-05-26 | 2020-05-26 | |
| US202063113116P | 2020-11-12 | 2020-11-12 | |
| US202163146555P | 2021-02-05 | 2021-02-05 | |
| PCT/US2021/033743 WO2021237143A1 (en) | 2020-05-22 | 2021-05-21 | Treatment of non-alcoholic steatohepatitis (nash) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022022737A2 true BR112022022737A2 (pt) | 2023-01-31 |
Family
ID=78707644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022022737A BR112022022737A2 (pt) | 2020-05-22 | 2021-05-21 | Tratamento de esteatose hepática não alcoólica (ehna) |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230181601A1 (enExample) |
| EP (1) | EP4153164A4 (enExample) |
| JP (1) | JP2023527153A (enExample) |
| KR (1) | KR20230015939A (enExample) |
| CN (1) | CN115916181A (enExample) |
| AU (1) | AU2021273936A1 (enExample) |
| BR (1) | BR112022022737A2 (enExample) |
| CA (1) | CA3195103A1 (enExample) |
| MX (1) | MX2022014575A (enExample) |
| TW (1) | TW202210081A (enExample) |
| WO (1) | WO2021237143A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL298681A (en) | 2016-08-02 | 2023-01-01 | Univ Virginia Commonwealth | Preparations |
| CN115103591B (zh) | 2019-12-27 | 2026-06-19 | 度勒科特公司 | 结晶性和液体结晶性25-羟基-胆甾-5-烯-3-硫酸钠及其制备方法 |
| CA3187310A1 (en) | 2020-06-26 | 2021-12-30 | Durect Corporation | Use of oxygenated cholesterol sulfates for treating autoimmune conditions |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI20848A (sl) * | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
| WO2006047022A1 (en) * | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
| US8399441B2 (en) * | 2004-10-25 | 2013-03-19 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis |
| US9034859B2 (en) * | 2011-04-06 | 2015-05-19 | Virginia Commonwealth University | Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation |
| CA2848711C (en) * | 2011-09-16 | 2019-08-06 | Galectin Therapeutics, Inc. | Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease |
| KR20150127599A (ko) * | 2013-03-15 | 2015-11-17 | 모치다 세이야쿠 가부시키가이샤 | 비알코올성 지방간염을 치료하기 위한 조성물 및 방법 |
| IL298681A (en) * | 2016-08-02 | 2023-01-01 | Univ Virginia Commonwealth | Preparations |
| WO2018026837A1 (en) * | 2016-08-02 | 2018-02-08 | Durect Corporation | Compositions comprising oxygenated cholesterol sulfate and at least one of polyalkylene glycol, carboxymethyl cellulose and polyoxylglyceride |
| CA3058542A1 (en) * | 2017-04-18 | 2018-10-25 | Genfit | Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor |
| CN111182904A (zh) * | 2017-10-06 | 2020-05-19 | 吉利德科学公司 | 包含acc抑制剂的组合治疗 |
-
2021
- 2021-05-21 JP JP2022570474A patent/JP2023527153A/ja active Pending
- 2021-05-21 WO PCT/US2021/033743 patent/WO2021237143A1/en not_active Ceased
- 2021-05-21 MX MX2022014575A patent/MX2022014575A/es unknown
- 2021-05-21 KR KR1020227043976A patent/KR20230015939A/ko active Pending
- 2021-05-21 TW TW110118457A patent/TW202210081A/zh unknown
- 2021-05-21 CN CN202180049351.XA patent/CN115916181A/zh active Pending
- 2021-05-21 AU AU2021273936A patent/AU2021273936A1/en active Pending
- 2021-05-21 EP EP21808175.0A patent/EP4153164A4/en active Pending
- 2021-05-21 BR BR112022022737A patent/BR112022022737A2/pt not_active Application Discontinuation
- 2021-05-21 US US17/924,101 patent/US20230181601A1/en active Pending
- 2021-05-21 CA CA3195103A patent/CA3195103A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115916181A (zh) | 2023-04-04 |
| CA3195103A1 (en) | 2021-11-25 |
| US20230181601A1 (en) | 2023-06-15 |
| KR20230015939A (ko) | 2023-01-31 |
| TW202210081A (zh) | 2022-03-16 |
| EP4153164A4 (en) | 2024-06-26 |
| JP2023527153A (ja) | 2023-06-27 |
| WO2021237143A1 (en) | 2021-11-25 |
| EP4153164A1 (en) | 2023-03-29 |
| AU2021273936A1 (en) | 2022-12-08 |
| MX2022014575A (es) | 2022-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022023128A2 (pt) | Tratamento da esteato-hepatite não alcoólica (nash) | |
| BR112022005039A2 (pt) | Tratamento de hepatite alcoólica | |
| MX2024000780A (es) | Anticuerpo anti-pd-1 para usarse en el tratamiento de cancer de pulmon. | |
| BR112022007595A2 (pt) | Métodos para tratar doença de alzheimer | |
| BR112018070676A2 (pt) | construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos | |
| BR112020016331A8 (pt) | Métodos para tratar câncer com anticorpos anti-pd-1 | |
| BR112018015413A2 (pt) | inibidores de indoleamina-2,3-dioxigenase (ido) | |
| BR112023026747A2 (pt) | Métodos e composições para direcionamento de pd-l1 | |
| BR112013021566A2 (pt) | composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula | |
| BR112022003956A2 (pt) | Anticorpos anti-cd73 | |
| CO2017001875A2 (es) | Terapia de combinación contra el alzheimer usando anticuerpos anti-n3pglu más un inhibidor bace | |
| BR112021021224A2 (pt) | Anticorpos ou fragmentos de anticorpos, composição farmacêutica, kit, ácido nucleico ou conjunto de ácidos nucleicos, célula hospedeira recombinante e método para o tratamento ou a prevenção de uma doença em um paciente em necessidade do mesmo | |
| BR112021021726A2 (pt) | Ribosídeos de nicotinamida reduzidos para tratamento/prevenção de doença hepática | |
| BR112015020600A2 (pt) | composição farmacêutica, método para o tratamento de e/ou melhorar doenças de gordura no fígado de origem não alcoólica e uso da composição | |
| BR112022024156A2 (pt) | Compostos heterocílicos antelmínticos | |
| PH12021551326A1 (en) | Rnai constructs for inhibiting pnpla3 expression | |
| BR112018003232A2 (pt) | terapias de combinação para tratamento de câncer | |
| RU2018124487A (ru) | Лечение внутрипеченочного холестаза и родственных заболеваний печени | |
| PH12020551076A1 (en) | Methods for treating diabetes, hepatitis, and/or inflammatory liver disease | |
| BR112015023086A2 (pt) | anticorpo anti-cd25 monoclonal ou um fragmento ligante anti-cd25 de um anticorpo monoclonal, conjugado de anticorpo-droga, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, métodos para produção de um anticorpo anti-cd25 ou fragmento ligante anti cd25, para prevenção de rejeição de órgãos transplantados e para tratamento de uma doença. | |
| BR112018072716A2 (pt) | molécula de ácido nucleico, composição, e, métodos para tratar uma doença e para prevenir ou tratar a formação de um biofilme. | |
| EA201990438A1 (ru) | Композиции, содержащие 5-холестен-3,25-диол, 3-сульфат (25hc3s) или его фармацевтически приемлемую соль и по меньшей мере один циклический олигосахарид, и способы их применения | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| BR112021025531A2 (pt) | Moduladores de pirazol-piridona farmacêuticamente ativos da nedilação de cullin mediada por dcn1/2 | |
| BR102014029197A8 (pt) | conjugado, seu processo de obtenção, uso, composição farmacêutica, ácido nucléico, vetor e célula hospedeira. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |